Biomedical Engineering Reference
In-Depth Information
alveolar macrophages from COPD patients. Am J Respir Crit Care Med 2002;
167:24-31.
105. Rahman I, Marwick JA, Kirkham PA. Redox modulation of histone acetyla-
tion and deacetylation in vitro and in vivo: modulation of NF-
k
B and pro-
inflammatory genes. Biochem Pharmacol 2004; 68:1255-1267.
106. Compton CH, Gubb J, Cedar E, Nieman RB, Amit O, Brambila C, Ayres J.
SB 207499, a second generation oral PDE4 inhibitor, first demonstration of
efficacy in patients with COPD. Eur Respir J 1999; 14:281s.
107. Chabrier P-E, Auguet M, Spinnewyn B, Auvin S, Cornet S, Demerle-Pallardy
C, Guilmard-Favre C, Marin J-G, Pignol B, Gillard-Roubert V, Roussillot-
Charnet C, Schulz J, Voissat I, Bigg D, Moncada S. BN 80933, a dual
inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising
neuroprotective strategy. Proc Natl Acad Sci USA 1999; 96:10824-10829.
108. Smith KR, Uyeminami DL, Kodavanti UP, Crapo JD, Chang LY, Pinkerton
KE. Inhibition of tobacco smoke-induced lung inflammation by a catalytic
antioxidant. Free Radic Biol Med 2002; 15:1106-1114.
109. Nishikawa M, Kakemizu N, Ito T, Kudo M, Kaneko T, Suzuki M, Udaka N,
Ikeda H, Okubo T. Superoxide mediates cigarette smoke-induced infiltration
of neutrophils into the airways through nuclear factor-
k
B activation and IL-8
mRNA expression in guinea pigs in vivo. Am J Respir Cell Mol Biol 1999;
20:189-198.
110. Lykkesfeldt J, Christen S, Wallock LM, Chang HH, Jacob RA, Ames BN.
Ascorbate is depleted by smoking and repleted by moderate supplementation:
a study in male smokers and nonsmokers with matched dietary antioxidant
intakes. Am J Clin Nutr 2000; 71:530-536.
111. Steinberg FM, Chait A. Antioxidant vitamin supplementation and lipid
peroxidation in smokers. Am J Clin Nutr 1998; 68:319-327.
112. Dietrich M, Block G, Hudes M, Morrow JD, Norkus EP, Traber MG, Cross
CE, Packer L. Antioxidant supplementation decreases lipid peroxidation
biomarker F
2
-isoprostanes in plasma of smokers. Cancer Epidemiol Biomar-
kers Prev 2002; 11:7-13.
113. Bridgemen MME, Marsden M, Selby C. Effect of N-acetylcysteine on the
concentrations of thiols in plasma bronchoalveolar lavage fluid and lining
tissue. Thorax 1994; 49:670-675.
114. Rasmusse JB, Glennow C. Reduction in days of illness after long-term treat-
ment with N-acetylcysteine controlled-release tablets in patients with chronic
bronchitis. Eur J Respir Dis 1988; 1:351-355.
115. British Thoracic Society Research Committee. Oral N-acetylcysteine and
exacerbation rates in patients with chronic bronchitis and severe airways
obstruction. Thorax 1985; 40:823-835.
116. Dueholm M, Nielson C, Thorshauge H, Evald T, Hansen NC, Madsen HD,
Maltbeck N. N-acetylcysteine by metred dose inhaler in the treatment of
chronic bronchitis: a multi-centre study. Respir Med 1992; 86:98-92.
117. Van Schooten FJ, Nia AB, De Flora S, D'Agostini F, Izzotti A, Camoirano
A, Balm AJ, Dallinga JW, Bast A, Haenen GR, Van't Veer L, Baas P, Sakai
H, Van Zandwijk N. Effects of oral administration of N-acetyl-l-cysteine: a
